One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Immune-Mediated Diseases Associated With Cancer Risks
Ming-ming He, MD; Chun-Han Lo, MD, MPH; Kai Wang, MD, PhD; et al.
Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades
Sophia C. Kamran, MD; Andrzej Niemierko, PhD; Curtiland Deville Jr, MD; et al.
Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving ImmunotherapyA Pooled Analysis of Trials in the US Food and Drug Administration Database
Mitchell S. Anscher, MD; Shaily Arora, PharmD; Chana Weinstock, MD; et al.
Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine–Refractory Differentiated Thyroid CancerThe REALITY Randomized Clinical Trial
Yansong Lin, MD, PhD; Shukui Qin, MD, PhD; Zhiyong Li, MM; et al.
Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in ChinaA Randomized Clinical Trial
Xiangyun Zong, MD, PhD; Yang Yu, MD; Hongjian Yang, MD; et al.
Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade GliomaA Phase 3 Randomized Clinical Trial
Alyx B. Porter, MD; Heshan Liu, MS; Sadhna Kohli, PhD; et al.
Association of Antiparietal Cell and Anti-Intrinsic Factor Antibodies With Risk of Gastric Cancer
Minkyo Song, MD, PhD; M. Constanza Camargo, PhD; Hormuzd A. Katki, PhD; et al.
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Robert J. Motzer, MD; Thomas Powles, MD; Michael B. Atkins, MD; et al.
Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With CancerA US Nationwide Veterans Affairs Study
Julie Tsu-Yu Wu, MD, PhD; Jennifer La, PhD; Westyn Branch-Elliman, MD, MMSc; et al.
Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment
Yakir Rottenberg, MD, MPH; Albert Grinshpun, MD, MSc; Iddo Z. Ben-Dov, MD, PhD; et al.
Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies
Samantha Brown, MS; Jessica A. Lavery, MS; Ronglai Shen, PhD; et al.
Treatment Selection in First-line Metastatic Renal Cell Carcinoma—The Contemporary Treatment Paradigm in the Age of Combination TherapyA Review
Vishal Navani, MA, MBBS, MRCP; Daniel Y. C. Heng, MD, MPH
Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination
Evangelos Terpos, MD, PhD; S. Vincent Rajkumar, MD; Nelson Leung, MD
Reconceptualizing Risk-Benefit Assessment of Novel Cancer Therapies to Expand Global Access and Reduce Worldwide Mortality
Rebecca J. DeBoer, MD, MA; Hope S. Rugo, MD; Lawrence N. Shulman, MD
The Urgent Need for Affordability Curricula at US Medical SchoolsThe Cost of Avoiding Cost for the Next Generation of Physicians
Palak V. Patel, BS, BA; Alexa L. Lacy, BS; Fumiko Chino, MD
Insights Into Immune-Mediated Disease and Cancer Risk—Delivering on the Promise of UK Biobank Big Data
Douglas R. Stewart, MD
Solving the Equation of Structural Inequities in the Oncology Workforce
Frederick Lansigan, MD; Charles R. Thomas Jr, MD
When Radiotherapy and Immunotherapy Dance—Who Leads So as Not to Step on Toes?
Fiyinfolu Balogun, MD, PhD; David Raben, MD
Treatment for Advanced and Metastatic Thyroid Cancer Refractory to Standard Treatment—We Need to Know the When, What, and Who
Electron Kebebew, MD
Carboplatin During Craniospinal Radiotherapy for Children With Group 3 Medulloblastoma—A New Standard of Care?
Matthias A. Karajannis, MD, MS; Audrey Mauguen, PhD; Kim Kramer, MD
Carboplatin During Craniospinal Radiotherapy for Children With Group 3 Medulloblastoma—A New Standard of Care?—Reply
Sarah E. S. Leary, MD; Yimei Li, PhD; James M. Olson, MD, PhD
Metformin—A Thought-provoking Addition to Anticancer Therapies
Jiaqi Liang, PhD; Cheng Zhan, PhD; Qun Wang, PhD
Metformin—A Thought-provoking Addition to Anticancer Therapies—Reply
Theodoros Tsakiridis, MD, PhD; Gregory R. Pond, PhD, PStat; James Wright, MD
Definitive Chemoradiotherapy for Older Patients With Esophageal Cancer
Tairo Kashihara, MD, PhD; Hiroto Ishiki, MD; Ken Kato, MD, PhD
Definitive Chemoradiotherapy for Older Patients With Esophageal Cancer
Masato Hayashi, MD; Naohiro Okano, MD, PhD; Tomonori Mizutani, MD, PhD
Definitive Chemoradiotherapy for Older Patients With Esophageal Cancer—Reply
Yongling Ji, MD; Xianghui Du, MD; Ming Chen, MD
